INKT icon

MiNK Therapeutics

8.97 USD
-0.25
2.71%
At close Apr 2, 4:00 PM EDT
1 day
-2.71%
5 days
1.70%
1 month
2.05%
3 months
-11.19%
6 months
20.40%
Year to date
-11.19%
1 year
-4.57%
5 years
-92.53%
10 years
-92.53%
 

About: MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.

Employees: 23

0
Funds holding %
of 7,398 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

0.1% less ownership

Funds ownership: 2.14% [Q3] → 2.04% (-0.1%) [Q4]

11% less capital invested

Capital invested by funds: $632K [Q3] → $565K (-$67.4K) [Q4]

12% less funds holding

Funds holding: 26 [Q3] → 23 (-3) [Q4]

33% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 6

60% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 5

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$35
290%
upside
Avg. target
$35
290%
upside
High target
$35
290%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Emily Bodnar
18% 1-year accuracy
29 / 163 met price target
290%upside
$35
Buy
Reiterated
18 Mar 2025

Financial journalist opinion

Based on 3 articles about INKT published over the past 30 days

Neutral
Seeking Alpha
2 weeks ago
MiNK Therapeutics, Inc. (INKT) Q4 2024 Earnings Call Transcript
MiNK Therapeutics, Inc. (NASDAQ:INKT ) Q4 2024 Earnings Conference Call March 18, 2025 8:30 AM ET Company Participants Zack Armen - Investor Relations Dr. Jennifer Buell - President and CEO Christine Klaskin - Principal Financial and Accounting Officer Conference Call Participants Emily Bodnar - H.C. Wainwright Mayank Mamtani - B.
MiNK Therapeutics, Inc. (INKT) Q4 2024 Earnings Call Transcript
Neutral
GlobeNewsWire
2 weeks ago
MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced its financial results for the fourth quarter and full year 2024, highlighting significant business progress and clinical advancements. The company will host a conference call and webcast at 8:30 a.m. ET.
MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress
Neutral
GlobeNewsWire
4 weeks ago
MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report
NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its fourth quarter and year end 2024 financial results before the market opens on Tuesday, March 18th. MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update.
MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report
Neutral
GlobeNewsWire
1 month ago
MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting
Addition of AgenT-797 with Checkpoint Inhibitors, BOT/BAL, and Chemotherapy Demonstrates Robust Immune Activation, Offering Potential to Overcome Refractory Gastric Cancers Addition of AgenT-797 with Checkpoint Inhibitors, BOT/BAL, and Chemotherapy Demonstrates Robust Immune Activation, Offering Potential to Overcome Refractory Gastric Cancers
MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting
Neutral
GlobeNewsWire
1 month ago
MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting
NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that it has been selected for an oral presentation at the upcoming American Association for Cancer Research (AACR) IO Annual Meeting that will take place on February 23-26 in Los Angeles, California. The oral presentation will highlight interim data from the company's ongoing Phase 2 study testing AgenT-797 in combination with Agenus' lead therapeutic combination, botensilimab and balstilimab (BOT/BAL), in patients with refractory (2L+) gastric cancer (NCT06251973).
MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting
Neutral
GlobeNewsWire
2 months ago
MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI
NEW YORK, Jan. 23, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced a presentation at the American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) Symposium in San Francisco, California.
MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI
Neutral
GlobeNewsWire
3 months ago
MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting
Presentation will feature the ongoing Phase 2 study of agenT-797 in refractory gastric cancer Presentation will feature the ongoing Phase 2 study of agenT-797 in refractory gastric cancer
MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting
Neutral
Seeking Alpha
4 months ago
MiNK Therapeutics, Inc. (INKT) Q3 2024 Earnings Conference Call Transcript
MiNK Therapeutics, Inc. (NASDAQ:INKT ) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Alexa Buffa - Corporate Communications Jennifer Buell - President and Chief Executive Officer Christine Klaskin - Principal Financial and Accounting Officer Paul Ibbett - Scientist Conference Call Participants Emily Bodnar - H.C. Wainwright Operator Thank you for standing by.
MiNK Therapeutics, Inc. (INKT) Q3 2024 Earnings Conference Call Transcript
Neutral
GlobeNewsWire
4 months ago
MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report
NEW YORK, Nov. 11, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its third quarter 2024 financial results before the market opens on November 14, 2024. MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and to provide a corporate update.
MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report
Neutral
GlobeNewsWire
4 months ago
MiNK's iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024
AgenT-797 Combination with Checkpoint Inhibitors and Bispecific Engagers Expands Anti-Cancer Benefit PRAME-TCR iNKT Overcomes Challenges from Conventional TCR-T Cells in Solid Cancers NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced data from two poster presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting in Houston, Texas. The presentations showcased new data from MiNK's iNKT cell therapy programs, agenT-797 and PRAME-TCR.
MiNK's iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024
Charts implemented using Lightweight Charts™